SEARCH:   Advanced

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Dohner, H Articles by Stilgenbauer, S Search for Related Content PubMed PubMed Citation Articles by Dohner, H Articles by Stilgenbauer, S Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias H Dohner, K Fischer, M Bentz, K Hansen, A Benner, G Cabot, D Diehl, R Schlenk, J Coy and S Stilgenbauer Medizinische Klinik, University of Heidelberg, Germany. Conventional cytogenetic analysis in B-cell chronic lymphocytic leukemia (B-CLL) has been very difficult, and the prognostic significance of specific chromosome aberrations is under discussion. Recent improvements in fluorescence in situ hybridization (ISH) techniques have provided an alternative approach for the detection of chromosome aberrations. Here, an interphase cytogenetic study was performed to analyze the incidence and prognostic significance of a p53 gene deletion in B-CLL and related disorders. We studied mononuclear cells from 100 patients with chronic B-cell leukemias [B-CLL, 90 patients; B-prolymphocytic leukemia (B-PLL), 7; Waldenstrom's macroglobulinemia (WM), 3] by fluorescence ISH with a genomic p53 DNA probe. In a subset of patients, additional G-banding analysis and single strand conformation polymorphism (SSCP) analysis was performed. Seventeen of the 100 patients [17%; B-CLL, 11 of 90 (12%); WM, 1 of 3; B-PLL, 5 of 7] exhibited a monoallelic p53 gene deletion by ISH. G- banding analysis demonstrated abnormalities of chromosome 17 in 13 of these 17 patients, all leading to loss of band 17p13. SSCP analysis showed aberrant bands in 9 of 14 patients with a p53 gene deletion. None of 12 patients with a p53 gene deletion compared with 20 of 36 patients (56%) without a deletion responded to therapy with fludarabine or pentostatin (P < .001). The difference in survival probabilities from the time of diagnosis and from the start of treatment with purine analogs between the two groups was highly significant (P < .001). In multivariate analysis, p53 gene deletion was the strongest prognostic factor for survival. In conclusion, p53 gene deletion predicts for non- response to therapy with purine analogs and for poor survival in chronic B-cell leukemias. Volume 85, Issue 6, pp. 1580-1589, 03/15/1995 Copyright © 1995 by The American Society of Hematology CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. R. Friedman, J. B. Weinberg, W. T. Barry, B. K. Goodman, A. D. Volkheimer, K. M. Bond, Y. Chen, N. Jiang, J. O. Moore, J. P. Gockerman, et al. A Genomic Approach to Improve Prognosis and Predict Therapeutic Response in Chronic Lymphocytic Leukemia Clin. Cancer Res., November 15, 2009; 15(22): 6947 - 6955. [Abstract] [Full Text] [PDF] A. M. McElligott, E. N. Maginn, L. M. Greene, S. McGuckin, A. Hayat, P. V. Browne, S. Butini, G. Campiani, M. A. Catherwood, E. Vandenberghe, et al. The Novel Tubulin-Targeting Agent Pyrrolo-1,5-Benzoxazepine-15 Induces Apoptosis in Poor Prognostic Subgroups of Chronic Lymphocytic Leukemia Cancer Res., November 1, 2009; 69(21): 8366 - 8375. [Abstract] [Full Text] [PDF] B. F. Eichhorst, R. Busch, S. Stilgenbauer, M. Stauch, M. A. Bergmann, M. Ritgen, N. Kranzhofer, R. Rohrberg, U. Soling, O. Burkhard, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia Blood, October 15, 2009; 114(16): 3382 - 3391. [Abstract] [Full Text] [PDF] J. Delgado, D. W. Milligan, and P. Dreger Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time? Blood, September 24, 2009; 114(13): 2581 - 2588. [Abstract] [Full Text] [PDF] T. Zenz, S. Habe, T. Denzel, J. Mohr, D. Winkler, A. Buhler, A. Sarno, S. Groner, D. Mertens, R. Busch, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial Blood, September 24, 2009; 114(13): 2589 - 2597. [Abstract] [Full Text] [PDF] S. Stilgenbauer, T. Zenz, D. Winkler, A. Buhler, R. F. Schlenk, S. Groner, R. Busch, M. Hensel, U. Duhrsen, J. Finke, et al. Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group J. Clin. Oncol., August 20, 2009; 27(24): 3994 - 4001. [Abstract] [Full Text] [PDF] C. S. Tam, T. D. Shanafelt, W. G. Wierda, L. V. Abruzzo, D. L. Van Dyke, S. O'Brien, A. Ferrajoli, S. A. Lerner, A. Lynn, N. E. Kay, et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience Blood, July 30, 2009; 114(5): 957 - 964. [Abstract] [Full Text] [PDF] G. G. Johnson, P. D. Sherrington, A. Carter, K. Lin, T. Liloglou, J. K. Field, and A. R. Pettitt A Novel Type of p53 Pathway Dysfunction in Chronic Lymphocytic Leukemia Resulting from Two Interacting Single Nucleotide Polymorphisms within the p21 Gene Cancer Res., June 15, 2009; 69(12): 5210 - 5217. [Abstract] [Full Text] [PDF] T. Zenz, J. Mohr, E. Eldering, A. P. Kater, A. Buhler, D. Kienle, D. Winkler, J. Durig, M. H. J. van Oers, D. Mertens, et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia Blood, April 16, 2009; 113(16): 3801 - 3808. [Abstract] [Full Text] [PDF] D. Sampath, G. A. Calin, V. K. Puduvalli, G. Gopisetty, C. Taccioli, C.-G. Liu, B. Ewald, C. Liu, M. J. Keating, and W. Plunkett Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation Blood, April 16, 2009; 113(16): 3744 - 3753. [Abstract] [Full Text] [PDF] M. Lopez-Guerra, G. Roue, P. Perez-Galan, R. Alonso, N. Villamor, E. Montserrat, E. Campo, and D. Colomer p65 Activity and ZAP-70 Status Predict the Sensitivity of Chronic Lymphocytic Leukemia Cells to the Selective I{kappa}B Kinase Inhibitor BMS-345541 Clin. Cancer Res., April 15, 2009; 15(8): 2767 - 2776. [Abstract] [Full Text] [PDF] M. A. Phelps, T. S. Lin, A. J. Johnson, E. Hurh, D. M. Rozewski, K. L. Farley, D. Wu, K. A. Blum, B. Fischer, S. M. Mitchell, et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia Blood, March 19, 2009; 113(12): 2637 - 2645. [Abstract] [Full Text] [PDF] D. Rossi, M. Cerri, C. Deambrogi, E. Sozzi, S. Cresta, S. Rasi, L. De Paoli, V. Spina, V. Gattei, D. Capello, et al. The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness Clin. Cancer Res., February 1, 2009; 15(3): 995 - 1004. [Abstract] [Full Text] [PDF] R. Sargent, D. Jones, L. V. Abruzzo, H. Yao, J. Bonderover, M. Cisneros, W. G. Wierda, M. J. Keating, and R. Luthra Customized Oligonucleotide Array-Based Comparative Genomic Hybridization as a Clinical Assay for Genomic Profiling of Chronic Lymphocytic Leukemia J. Mol. Diagn., January 1, 2009; 11(1): 25 - 34. [Abstract] [Full Text] [PDF] T. J. Kipps Chronic Lymphocytic Leukemia: Advances in Assessing Prognosis and Therapy ASCO Educational Book, January 1, 2009; 2009(1): 385 - 393. [Abstract] [Full Text] [PDF] M. Lopez-Guerra, L. Trigueros-Motos, M. Molina-Arcas, N. Villamor, F. J. Casado, E. Montserrat, E. Campo, D. Colomer, and M. Pastor-Anglada Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells Haematologica, December 1, 2008; 93(12): 1843 - 1851. [Abstract] [Full Text] [PDF] J. Schetelig, A. van Biezen, R. Brand, D. Caballero, R. Martino, M. Itala, J. A. Garcia-Marco, L. Volin, N. Schmitz, R. Schwerdtfeger, et al. Allogeneic Hematopoietic Stem-Cell Transplantation for Chronic Lymphocytic Leukemia With 17p Deletion: A Retrospective European Group for Blood and Marrow Transplantation Analysis J. Clin. Oncol., November 1, 2008; 26(31): 5094 - 5100. [Abstract] [Full Text] [PDF] T. Zenz, A. Krober, K. Scherer, S. Habe, A. Buhler, A. Benner, T. Denzel, D. Winkler, J. Edelmann, C. Schwanen, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up Blood, October 15, 2008; 112(8): 3322 - 3329. [Abstract] [Full Text] [PDF] L. Kujawski, P. Ouillette, H. Erba, C. Saddler, A. Jakubowiak, M. Kaminski, K. Shedden, and S. N. Malek Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia Blood, September 1, 2008; 112(5): 1993 - 2003. [Abstract] [Full Text] [PDF] C. S. Tam, S. O'Brien, W. Wierda, H. Kantarjian, S. Wen, K.-A. Do, D. A. Thomas, J. Cortes, S. Lerner, and M. J. Keating Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia Blood, August 15, 2008; 112(4): 975 - 980. [Abstract] [Full Text] [PDF] M. Hallek, B. D. Cheson, D. Catovsky, F. Caligaris-Cappio, G. Dighiero, H. Dohner, P. Hillmen, M. J. Keating, E. Montserrat, K. R. Rai, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines Blood, June 15, 2008; 111(12): 5446 - 5456. [Abstract] [Full Text] [PDF] I. Gryshchenko, S. Hofbauer, M. Stoecher, P. T. Daniel, M. Steurer, A. Gaiger, K. Eigenberger, R. Greil, and I. Tinhofer MDM2 SNP309 Is Associated With Poor Outcome in B-Cell Chronic Lymphocytic Leukemia J. Clin. Oncol., May 10, 2008; 26(14): 2252 - 2257. [Abstract] [Full Text] [PDF] C. Saddler, P. Ouillette, L. Kujawski, S. Shangary, M. Talpaz, M. Kaminski, H. Erba, K. Shedden, S. Wang, and S. N. Malek Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia Blood, February 1, 2008; 111(3): 1584 - 1593. [Abstract] [Full Text] [PDF] A. M. Tsimberidou, W. G. Wierda, W. Plunkett, R. Kurzrock, S. O'Brien, S. Wen, A. Ferrajoli, F. Ravandi-Kashani, G. Garcia-Manero, Z. Estrov, et al. Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia J. Clin. Oncol., January 10, 2008; 26(2): 196 - 203. [Abstract] [Full Text] [PDF] T. J. Kipps Chronic Lymphocytic Leukemia: Prognostic Markers and Revised Criteria for Treatment and Response Assessment ASCO Educational Book, January 1, 2008; 2008(1): 286 - 290. [Abstract] [Full Text] [PDF] K. H. Young, D. D. Weisenburger, B. J. Dave, L. Smith, W. Sanger, J. Iqbal, E. Campo, J. Delabie, R. D. Gascoyne, G. Ott, et al. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma Blood, December 15, 2007; 110(13): 4396 - 4405. [Abstract] [Full Text] [PDF] P. Hillmen, A. B. Skotnicki, T. Robak, B. Jaksic, A. Dmoszynska, J. Wu, C. Sirard, and J. Mayer Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia J. Clin. Oncol., December 10, 2007; 25(35): 5616 - 5623. [Abstract] [Full Text] [PDF] S. Stilgenbauer, S. Sander, L. Bullinger, A. Benner, E. Leupolt, D. Winkler, A. Krober, D. Kienle, P. Lichter, and H. Dohner Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival Haematologica, September 1, 2007; 92(9): 1242 - 1245. [Abstract] [Full Text] [PDF] M. R. Grever, D. M. Lucas, G. W. Dewald, D. S. Neuberg, J. C. Reed, S. Kitada, I. W. Flinn, M. S. Tallman, F. R. Appelbaum, R. A. Larson, et al. Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997 J. Clin. Oncol., March 1, 2007; 25(7): 799 - 804. [Abstract] [Full Text] [PDF] J. C. Byrd, T. S. Lin, J. T. Dalton, D. Wu, M. A. Phelps, B. Fischer, M. Moran, K. A. Blum, B. Rovin, M. Brooker-McEldowney, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia Blood, January 15, 2007; 109(2): 399 - 404. [Abstract] [Full Text] [PDF] F. Dicker, S. Schnittger, T. Haferlach, W. Kern, and C. Schoch Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression Blood, November 1, 2006; 108(9): 3152 - 3160. [Abstract] [Full Text] [PDF] T. D. Shanafelt, T. E. Witzig, S. R. Fink, R. B. Jenkins, S. F. Paternoster, S. A. Smoley, K. J. Stockero, D. M. Nast, H. C. Flynn, R. C. Tschumper, et al. Prospective Evaluation of Clonal Evolution During Long-Term Follow-Up of Patients With Untreated Early-Stage Chronic Lymphocytic Leukemia J. Clin. Oncol., October 1, 2006; 24(28): 4634 - 4641. [Abstract] [Full Text] [PDF] K. Balakrishnan, R. Nimmanapalli, F. Ravandi, M. J. Keating, and V. Gandhi Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells Blood, October 1, 2006; 108(7): 2392 - 2398. [Abstract] [Full Text] [PDF] T. D. Shanafelt, J. C. Byrd, T. G. Call, C. S. Zent, and N. E. Kay Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. Ann Intern Med, September 19, 2006; 145(6): 435 - 447. [Abstract] [Full Text] [PDF] K. Lin, M. A. Glenn, R. J. Harris, A. D. Duckworth, S. Dennett, J. C. Cawley, M. Zuzel, and J. R. Slupsky c-Abl Expression in Chronic Lymphocytic Leukemia Cells: Clinical and Therapeutic Implications. Cancer Res., August 1, 2006; 66(15): 7801 - 7809. [Abstract] [Full Text] [PDF] K. Kojima, M. Konopleva, T. McQueen, S. O'Brien, W. Plunkett, and M. Andreeff Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia Blood, August 1, 2006; 108(3): 993 - 1000. [Abstract] [Full Text] [PDF] L. Coll-Mulet, D. Iglesias-Serret, A. F. Santidrian, A. M. Cosialls, M. de Frias, E. Castano, C. Campas, M. Barragan, A. F. de Sevilla, A. Domingo, et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells Blood, May 15, 2006; 107(10): 4109 - 4114. [Abstract] [Full Text] [PDF] P. Secchiero, E. Barbarotto, M. Tiribelli, C. Zerbinati, M. G. di Iasio, A. Gonelli, F. Cavazzini, D. Campioni, R. Fanin, A. Cuneo, et al. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL) Blood, May 15, 2006; 107(10): 4122 - 4129. [Abstract] [Full Text] [PDF] E. Montserrat, C. Moreno, J. Esteve, A. Urbano-Ispizua, E. Gine, and F. Bosch How I treat refractory CLL Blood, February 15, 2006; 107(4): 1276 - 1283. [Abstract] [Full Text] [PDF] J. V. Thottassery, L. Westbrook, H. Someya, and W. B. Parker c-Abl-independent p73 stabilization during gemcitabine- or 4'-thio-{beta}-D-arabinofuranosylcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells. Mol. Cancer Ther., February 1, 2006; 5(2): 400 - 410. [Abstract] [Full Text] [PDF] B. F. Eichhorst, R. Busch, G. Hopfinger, R. Pasold, M. Hensel, C. Steinbrecher, S. Siehl, U. Jager, M. Bergmann, S. Stilgenbauer, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia Blood, February 1, 2006; 107(3): 885 - 891. [Abstract] [Full Text] [PDF] J. C. Byrd, J. G. Gribben, B. L. Peterson, M. R. Grever, G. Lozanski, D. M. Lucas, B. Lampson, R. A. Larson, M. A. Caligiuri, and N. A. Heerema Select High-Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy With Fludarabine and Rituximab in Chronic Lymphocytic Leukemia: Justification for Risk-Adapted Therapy J. Clin. Oncol., January 20, 2006; 24(3): 437 - 443. [Abstract] [Full Text] [PDF] F. Ravandi and S. O'Brien Chronic Lymphoid Leukemias Other Than Chronic Lymphocytic Leukemia: Diagnosis and Treatment Mayo Clin. Proc., December 1, 2005; 80(12): 1660 - 1674. [Abstract] [PDF] A. Raval, D. M. Lucas, J. J. Matkovic, K. L. Bennett, S. Liyanarachchi, D. C. Young, L. Rassenti, T. J. Kipps, M. R. Grever, J. C. Byrd, et al. TWIST2 Demonstrates Differential Methylation in Immunoglobulin Variable Heavy Chain Mutated and Unmutated Chronic Lymphocytic Leukemia J. Clin. Oncol., June 10, 2005; 23(17): 3877 - 3885. [Abstract] [Full Text] [PDF] M. L. Sorror, M. B. Maris, B. M. Sandmaier, B. E. Storer, M. J. Stuart, U. Hegenbart, E. Agura, T. R. Chauncey, J. Leis, M. Pulsipher, et al. Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia J. Clin. Oncol., June 1, 2005; 23(16): 3819 - 3829. [Abstract] [Full Text] [PDF] T. D. Shanafelt, Y. K. Lee, N. D. Bone, A. K. Strege, V. L. Narayanan, E. A. Sausville, S. M. Geyer, S. H. Kaufmann, and N. E. Kay Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine Blood, March 1, 2005; 105(5): 2099 - 2106. [Abstract] [Full Text] [PDF] J. C. Byrd, K. Rai, B. L. Peterson, F. R. Appelbaum, V. A. Morrison, J. E. Kolitz, L. Shepherd, J. D. Hines, C. A. Schiffer, and R. A. Larson Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011 Blood, January 1, 2005; 105(1): 49 - 53. [Abstract] [Full Text] [PDF] C. Haslinger, N. Schweifer, S. Stilgenbauer, H. Dohner, P. Lichter, N. Kraut, C. Stratowa, and R. Abseher Microarray Gene Expression Profiling of B-Cell Chronic Lymphocytic Leukemia Subgroups Defined by Genomic Aberrations and VH Mutation Status J. Clin. Oncol., October 1, 2004; 22(19): 3937 - 3949. [Abstract] [Full Text] [PDF] A. Rosenwald, E. Y. Chuang, R. E. Davis, A. Wiestner, A. A. Alizadeh, D. C. Arthur, J. B. Mitchell, G. E. Marti, D. H. Fowler, W. H. Wilson, et al. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response Blood, September 1, 2004; 104(5): 1428 - 1434. [Abstract] [Full Text] [PDF] G. Lozanski, N. A. Heerema, I. W. Flinn, L. Smith, J. Harbison, J. Webb, M. Moran, M. Lucas, T. Lin, M. L. Hackbarth, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions Blood, May 1, 2004; 103(9): 3278 - 3281. [Abstract] [Full Text] [PDF] D. T. Jones, E. Addison, J. M. North, M. W. Lowdell, A. V. Hoffbrand, A. B. Mehta, K. Ganeshaguru, N. I. Folarin, and R. G. Wickremasinghe Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells' sensitivity to cytotoxic drugs Blood, March 1, 2004; 103(5): 1855 - 1861. [Abstract] [Full Text] [PDF] T. D. Shanafelt, S. M. Geyer, and N. E. Kay Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL Blood, February 15, 2004; 103(4): 1202 - 1210. [Abstract] [Full Text] [PDF] C. Schwaenen, M. Nessling, S. Wessendorf, T. Salvi, G. Wrobel, B. Radlwimmer, H. A. Kestler, C. Haslinger, S. Stilgenbauer, H. Dohner, et al. Automated array-based genomic profiling in chronic lymphocytic leukemia: Development of a clinical tool and discovery of recurrent genomic alterations PNAS, January 27, 2004; 101(4): 1039 - 1044. [Abstract] [Full Text] [PDF] J. C. Byrd, S. Stilgenbauer, and I. W. Flinn Chronic Lymphocytic Leukemia Hematology, January 1, 2004; 2004(1): 163 - 183. [Abstract] [Full Text] [PDF] G. Anether, I. Tinhofer, M. Senfter, and R. Greil Tetrocarcin-A--induced ER stress mediates apoptosis in B-CLL cells via a Bcl-2--independent pathway Blood, June 1, 2003; 101(11): 4561 - 4568. [Abstract] [Full Text] [PDF] B. Mavromatis and B. D. Cheson Monoclonal Antibody Therapy of Chronic Lymphocytic Leukemia J. Clin. Oncol., May 1, 2003; 21(9): 1874 - 1881. [Abstract] [Full Text] [PDF] C. Pepper, A. Thomas, T. Hoy, D. Milligan, P. Bentley, and C. Fegan The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro Blood, April 1, 2003; 101(7): 2454 - 2459. [Abstract] [Full Text] [PDF] J. C. Byrd, L. Smith, M. L. Hackbarth, I. W. Flinn, D. Young, J. H. Proffitt, and N. A. Heerema Interphase Cytogenetic Abnormalities in Chronic Lymphocytic Leukemia May Predict Response to Rituximab Cancer Res., January 1, 2003; 63(1): 36 - 38. [Abstract] [Full Text] [PDF] J. C. Byrd, B. L. Peterson, V. A. Morrison, K. Park, R. Jacobson, E. Hoke, J. W. Vardiman, K. Rai, C. A. Schiffer, and R. A. Larson Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712) Blood, January 1, 2003; 101(1): 6 - 14. [Abstract] [Full Text] [PDF] S. Bea, A. Lopez-Guillermo, M. Ribas, X. Puig, M. Pinyol, A. Carrio, L. Zamora, F. Soler, F. Bosch, S. Stilgenbauer, et al. Genetic Imbalances in Progressed B-Cell Chronic Lymphocytic Leukemia and Transformed Large-Cell Lymphoma (Richter's Syndrome) Am. J. Pathol., September 1, 2002; 161(3): 957 - 968. [Abstract] [Full Text] [PDF] S. Stilgenbauer and H. Dohner Campath-1H-Induced Complete Remission of Chronic Lymphocytic Leukemia despite p53 Gene Mutation and Resistance to Chemotherapy N. Engl. J. Med., August 8, 2002; 347(6): 452 - 453. [Full Text] [PDF] D. G. Oscier, A. C. Gardiner, S. J. Mould, S. Glide, Z. A. Davis, R. E. Ibbotson, M. M. Corcoran, R. M. Chapman, P. W. Thomas, J. A. Copplestone, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors Blood, July 30, 2002; 100(4): 1177 - 1184. [Abstract] [Full Text] [PDF] A. Krober, T. Seiler, A. Benner, L. Bullinger, E. Bruckle, P. Lichter, H. Dohner, and S. Stilgenbauer VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia Blood, July 30, 2002; 100(4): 1410 - 1416. [Abstract] [Full Text] [PDF] K. Lin, P. D. Sherrington, M. Dennis, Z. Matrai, J. C. Cawley, and A. R. Pettitt Relationship between p53 dysfunction, CD38 expression, and IgVH mutation in chronic lymphocytic leukemia Blood, July 30, 2002; 100(4): 1404 - 1409. [Abstract] [Full Text] [PDF] K. Leroy, C. Haioun, E. Lepage, N. Le Metayer, F. Berger, E. Labouyrie, V. Meignin, B. Petit, C. Bastard, G. Salles, et al. p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas Ann. Onc., July 1, 2002; 13(7): 1108 - 1115. [Abstract] [Full Text] [PDF] N. E. Kay, T. J. Hamblin, D. F. Jelinek, G. W. Dewald, J. C. Byrd, S. Farag, M. Lucas, and T. Lin Chronic Lymphocytic Leukemia Hematology, January 1, 2002; 2002(1): 193 - 213. [Abstract] [Full Text] A. R. Pettitt, P. D. Sherrington, G. Stewart, J. C. Cawley, A. M. R. Taylor, and T. Stankovic p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation Blood, August 1, 2001; 98(3): 814 - 822. [Abstract] [Full Text] [PDF] A. M. Gruszka-Westwood, R. A. Hamoudi, E. Matutes, E. Tuset, and D. Catovsky p53 abnormalities in splenic lymphoma with villous lymphocytes Blood, June 1, 2001; 97(11): 3552 - 3558. [Abstract] [Full Text] [PDF] K. R. Rai, H. Dohner, M. J. Keating, and E. Montserrat Chronic Lymphocytic Leukemia: Case-Based Session Hematology, January 1, 2001; 2001(1): 140 - 156. [Abstract] [Full Text] [PDF] H. Dohner, S. Stilgenbauer, A. Benner, E. Leupolt, A. Krober, L. Bullinger, K. Dohner, M. Bentz, and P. Lichter Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia N. Engl. J. Med., December 28, 2000; 343(26): 1910 - 1916. [Abstract] [Full Text] [PDF] A. R. Pettitt, P. D. Sherrington, and J. C. Cawley Role of Poly(ADP-ribosyl)ation in the Killing of Chronic Lymphocytic Leukemia Cells by Purine Analogues Cancer Res., August 1, 2000; 60(15): 4187 - 4193. [Abstract] [Full Text] M. A. Dimopoulos, P. Panayiotidis, L. A. Moulopoulos, P. Sfikakis, and M. Dalakas Waldenstrom’s Macroglobulinemia: Clinical Features, Complications, and Management J. Clin. Oncol., January 5, 2000; 18(1): 214 - 214. [Abstract] [Full Text] [PDF] Y. Xie, J. D. Gilbert, J. H. Kim, and S. O. Freytag Efficacy of Adenovirus-mediated CD/5-FC and HSV-1 Thymidine Kinase/Ganciclovir Suicide Gene Therapies Concomitant with p53 Gene Therapy Clin. Cancer Res., December 1, 1999; 5(12): 4224 - 4232. [Abstract] [Full Text] [PDF] B. Bellosillo, N. Villamor, D. Colomer, G. Pons, E. Montserrat, and J. Gil In Vitro Evaluation of Fludarabine in Combination With Cyclophosphamide and/or Mitoxantrone in B-Cell Chronic Lymphocytic Leukemia Blood, October 15, 1999; 94(8): 2836 - 2843. [Abstract] [Full Text] [PDF] N. Kalil and B. D. Cheson Chronic Lymphocytic Leukemia Oncologist, October 1, 1999; 4(5): 352 - 369. [Abstract] [Full Text] J. C. Byrd, C. Shinn, R. Ravi, C. R. Willis, J. K. Waselenko, I. W. Flinn, N. A. Dawson, and M. R. Grever Depsipeptide (FR901228): A Novel Therapeutic Agent With Selective, In Vitro Activity Against Human B-Cell Chronic Lymphocytic Leukemia Cells Blood, August 15, 1999; 94(4): 1401 - 1408. [Abstract] [Full Text] [PDF] A. Cuneo, R. Bigoni, G. M. Rigolin, M. G. Roberti, A. Bardi, N. Piva, R. Milani, F. Bullrich, M. L. Veronese, C. Croce, et al. Cytogenetic Profile of Lymphoma of Follicle Mantle Lineage: Correlation With Clinicobiologic Features Blood, February 15, 1999; 93(4): 1372 - 1380. [Abstract] [Full Text] [PDF] J. C. Byrd, C. Shinn, J. K. Waselenko, E. J. Fuchs, T. A. Lehman, P. L. Nguyen, I. W. Flinn, L. F. Diehl, E. Sausville, and M. R. Grever Flavopiridol Induces Apoptosis in Chronic Lymphocytic Leukemia Cells Via Activation of Caspase-3 Without Evidence of bcl-2 Modulation or Dependence on Functional p53 Blood, November 15, 1998; 92(10): 3804 - 3816. [Abstract] [Full Text] [PDF] J. Drach, J. Ackermann, E. Fritz, E. Kromer, R. Schuster, H. Gisslinger, M. DeSantis, N. Zojer, M. Fiegl, S. Roka, et al. Presence of a p53 Gene Deletion in Patients With Multiple Myeloma Predicts for Short Survival After Conventional-Dose Chemotherapy Blood, August 1, 1998; 92(3): 802 - 809. [Abstract] [Full Text] [PDF] T. F.E. Barth, H. Dohner, C. A. Werner, S. Stilgenbauer, M. Schlotter, M. Pawlita, P. Lichter, P. Moller, and M. Bentz Characteristic Pattern of Chromosomal Gains and Losses in Primary Large B-Cell Lymphomas of the Gastrointestinal Tract Blood, June 1, 1998; 91(11): 4321 - 4330. [Abstract] [Full Text] [PDF] I. Cordone, S. Masi, F. R. Mauro, S. Soddu, O. Morsilli, T. Valentini, M. L. Vegna, C. Guglielmi, F. Mancini, S. Giuliacci, et al. p53 Expression in B-Cell Chronic Lymphocytic Leukemia: A Marker of Disease Progression and Poor Prognosis Blood, June 1, 1998; 91(11): 4342 - 4349. [Abstract] [Full Text] [PDF] P. R.K. Koduru, K. Raju, V. Vadmal, G. Menezes, S. Shah, M. Susin, J. Kolitz, and J. D. Broome Correlation Between Mutation in P53, p53 Expression, Cytogenetics, Histologic Type, and Survival in Patients With B-Cell Non-Hodgkin's Lymphoma Blood, November 15, 1997; 90(10): 4078 - 4091. [Abstract] [Full Text] [PDF] J. F. DeCoteau, P. I. Knaus, H. Yankelev, M. D. Reis, R. Lowsky, H. F. Lodish, and M. E. Kadin Loss of functional cell surface transforming growth factor beta  (TGF-beta ) type 1 receptor correlates with insensitivity to TGF-beta in chronic lymphocytic leukemia PNAS, May 27, 1997; 94(11): 5877 - 5881. [Abstract] [Full Text] [PDF] H. Dohner, S. Stilgenbauer, M. R. James, A. Benner, T. Weilguni, M. Bentz, K. Fischer, W. Hunstein, and P. Lichter 11q Deletions Identify a New Subset of B-Cell Chronic Lymphocytic Leukemia Characterized by Extensive Nodal Involvement and Inferior Prognosis Blood, April 1, 1997; 89(7): 2516 - 2522. [Abstract] [Full Text] [PDF] K. Fischer, S. Frohling, S. W. Scherer, J. McAllister Brown, C. Scholl, S. Stilgenbauer, L.-C. Tsui, P. Lichter, and H. Dohner Molecular Cytogenetic Delineation of Deletions and Translocations Involving Chromosome Band 7q22 in Myeloid Leukemias Blood, March 15, 1997; 89(6): 2036 - 2041. [Abstract] [Full Text] [PDF] J. M. Kolesar, A. K. Morris, and J. G. Kuhn Review : Purine nucleoside analogues: Fludarabine, pentostatin, and cladribine: Part 1: Fludarabine Journal of Oncology Pharmacy Practice, January 1, 1996; 2(3): 160 - 181. [Abstract] [PDF] C. Rozman and E. Montserrat Chronic Lymphocytic Leukemia N. Engl. J. Med., October 19, 1995; 333(16): 1052 - 1057. [Full Text] [PDF]

	Copyright © 1995 by American Society of Hematology         Online ISSN: 1528-0020